Summit Therapeutics (NASDAQ: SMMT) has risen in prominence in the past two years thanks to a promising pipeline candidate, ivonescimab, a potential cancer treatment. The company's shares are up by 340%...
A five-bagger in only five years? Any investor would love to buy such a stock. Fortunes can be made quickly with those kinds of turbocharged performers.
Investing in biotech stocks usually isn't for the faint of heart. These stocks tend to be highly volatile because of the inherent risks of developing new drugs.
It's been a good year for the stock market as a whole and a tremendous year for a couple of drugmaker start-ups. Shares of Viking Therapeutics (NASDAQ: VKTX) and Summit Therapeutics (NASDAQ: SMMT) more...
Normally, you might expect to achieve significant gains from stocks if you invest in them for years, perhaps decades. But given how hot the stock market has been this year, some stocks have produced life-changing...
Summit Therapeutics (NASDAQ: SMMT) stock got a real shot in the arm Friday with the initiation of coverage by a veteran financial services company. On news that Jefferies is now tracking the stock, investors...
Do you ever wonder what America's wealthiest stock traders are buying and selling? Thanks to the Securities and Exchange Commission, you don't have to. Every three months, anyone with over $100 million...
Up 860% in the last 12 months alone, Summit Therapeutics (NASDAQ: SMMT) is a skyrocketing stock that likely has more upside in store.
Godzilla and King Kong surely weren't born big. They began small and grew over time to their gargantuan sizes even if the movies don't tell their childhood stories.
Markets rallied strongly this week on clarity about the election and an expected rate cut, but next week's inflation readings will determine if momentum lasts